Article

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review

2022-08-03

Abstract excerpt

Immunosuppressed patients have increased risk for morbidity and mortality from COVID-19 because they less frequently mount antibody responses to vaccines and often cannot tolerate small-molecule antivirals. The Omicron variant of concern of SARS-CoV-2 has progressively defeated anti-Spike mAbs authorized so far, paving the way to a return to COVID-19 convalescent plasma (CCP) therapy. In this systematic review we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 326e2ba3-1ee5-5e35-8d16-8024628aaefc
DOI: 10.1101/2022.08.03.22278359

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewDOI 10.1101/2022.08.03.22278359Read

Functional Antibodies in COVID-19 Convalescent PlasmaSemantic proximity Read

Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 Omicron SARS-CoV-2Semantic proximity Read

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19Semantic proximity Read

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal AntibodiesSemantic proximity Read

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read

A Role for Nucleocapsid-Specific Antibody Function in COVID-19 Convalescent Plasma TherapySemantic proximity Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read

Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agentsSemantic proximity Read

Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions.Semantic proximity Read

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.Semantic proximity Read